share_log

Nanox Launches Artificial Intelligence Functionality in Second Opinions Platform

Nanox Launches Artificial Intelligence Functionality in Second Opinions Platform

Nanox在第二意見平台中推出了人工智能功能。
Nano X Imaging ·  06/05 12:00

Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service

Nanox將經過FDA認證的人群健康人工智能解決方案整合進其“Second Opinions”服務中。它的Second Opinions服務

New AI capabilities available to patients who submit chest and abdominal CT scans for second opinions

可供提交胸部和腹部CT掃描的患者使用新的人工智能功能。a以促進提前檢測慢性疾病。該服務主張爲我們的二次診斷CT報告提供了人工智能的力量。

Offering the power of Artificial Intelligence to their second opinion CT report to promote early detection of chronic conditions

以促進慢性病的早期檢測。以此推廣。早期檢測慢性疾病

PETACH TIKVA, Israel, June 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., has launched an artificial intelligence (AI) functionality in the Second Opinions online medical consultation service. Second Opinions is a platform provided by USARAD Holdings INC, a subsidiary of Nano-X Imaging Ltd., that provides teleradiology services. The platform connects patients with radiologists and other subspecialty physicians for additional consultation on their medical diagnoses. Second Opinions has integrated three of Nanox.AI's FDA 510(k)-cleared AI solutions, enabling patients to conveniently get second opinions from experts in various medical and surgical subspecialties including radiology, neurology, oncology and orthopedic surgery. The integration of Nanox.AI's tools is intended to promote the early detection of chronic conditions on chest and abdominal CT scans:

以色列PETACH TIKVA,2024年6月5日(環球網通社) - 創新醫學成像製造行業公司納米·X成像有限公司(“Nanox”或“公司”,納斯達克:NNOX)今天宣佈,它的深度學習醫學成像分析子公司Nanox AI有限公司在Second Opinions在線醫療諮詢服務中推出了人工智能(AI)功能。Second Opinions是由Nano-X Imaging Ltd.的子公司USARAD Holdings INC提供的平台,提供遠程放射學服務,連接患者和放射學家以及其他醫療診斷專家進行相關醫療診斷的交流和諮詢,提升對患者醫療診斷的敏銳度和Globalease。Second Opinions已將Nanox.AI的三個FDA 510(k)許可的人工智能解決方案進行了集成,旨在使患者方便地獲得來自各種醫療和外科專業領域專家的第二意見,包括放射學,神經學,腫瘤學和骨科手術。Nanox.AI工具的集成旨在促進胸部和腹部CT掃描中慢性疾病的早期發現。

  • AI Cardiac solution (HealthCCSng) detects coronary artery calcium, an early sign of coronary artery disease
  • AI Bone solution (HealthOST) assesses bone mineral density, and highlights vertebral spine compression fractures which can indicate risk of osteoporosis
  • AI Liver solution (HealthFLD) measures liver density, which can indicate fatty liver disease
  • AI心臟解決方案(HealthCCSng)可以檢測冠狀動脈鈣化,這是冠狀動脈疾病的早期徵象
  • AI骨骼解決方案(HealthOST)可以評估骨密度,並突出顯示可指示骨質疏鬆症風險的椎體壓縮性骨折
  • AI肝解決方案(HealthFLD)可以測量肝密度,這可以指示脂肪肝病

These AI-driven insights are reviewed and approved by Second Opinions physicians and incorporated into reports for patients who submit eligible chest and abdominal CT scans.

這些基於AI的見解由Second Opinions醫生審查和批准,併合併到提交符合條件的胸部和腹部CT掃描的患者報告中。

"We are excited to bring AI-powered, early detection through the Second Opinions platform to patients seeking peace of mind concerning their health and diagnoses," said Erez Meltzer, Nanox Chief Executive Officer. "The integration of Nanox.AI's solutions into the Second Opinions service will help empower radiologists and other healthcare providers by providing them with advanced AI tools that aim to improve patient outcomes. We will continue exploring opportunities to leverage our AI technology to promote accessible early diagnosis and preventative management."

“我們很高興通過Second Opinions平台爲尋求關於其健康和診斷的安心的患者帶來AI支持的早期檢測。” Erez Meltzer 博士,Nanox首席執行官說。 “在Second Opinions服務中整合Nanox.AI的解決方案將有助於賦予放射科醫師和其他醫療保健提供者先進的AI工具,旨在改善患者預後。我們將繼續探索利用我們的AI技術促進可接近的早期診斷和預防管理的機會。”

Learn more about Second Opinions and its new AI capabilities at Artificial Intelligence (AI) Service - Second Opinions.

了解Second Opinions及其新的人工智能能力:人工智能(AI)服務-Second Opinions人工智能服務-Second Opinions.

About USARAD
USARAD is a U.S.-based teleradiology company with a network of radiologists, certified by the American Board of Radiology. USARAD provides imaging interpretation and database services to radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities and multi-specialty physician groups in the U.S and additional countries, improving service levels, streamlining practice economics and enhancing physician efficiency.

關於USARAD
USARAD是一家總部位於美國的遙感放射診斷公司,具有美國放射學委員會認證的放射科醫師網絡。 USARAD爲美國及其他國家的放射學實踐,醫院,醫療診所,診斷成像中心,急診護理設施和多門診醫師群體提供成像解釋和數據庫服務,提高服務水平,簡化實踐經濟學,並增強醫療效率。

About Nanox.AI
Nanox AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI technology, Nanox AI helps clinicians extract valuable and actionable clinical insights from routine medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit https://www.nanox.vision/ai.

關於Nanox.AI
Nanox AI是Nanox的深度學習醫學影像分析子公司。 Nanox.AI的解決方案旨在針對全球大量患者患有的高盛行慢性病和急性病。利用人工智能技術,Nanox AI幫助臨床醫生從常規醫學影像中提取有價值的且可行的臨床見解,這些見解常常會被忽視,從而可能引發進一步的醫療評估,以爲患者建立個體預防保健途徑。欲了解更多信息,請訪問。https://www.nanox.vision/ai.

About Nanox
Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox's vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease (Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox's subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox's products and services create a worldwide, innovative, and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision.

關於Nanox
納斯達克股票代碼NNOX的納諾-X(Nanox)致力於將其專有醫學成像技術和解決方案應用於全球診斷醫學的方便性和經濟性。 Nanox的願景是提高診斷醫學技術和流程的可訪問性,降低成本和提高效率,這被視爲改善早期檢測和治療的關鍵所在,而早期檢測和治療有助於使人們實現更好的健康結果,最終挽救生命。 Nanox生態系統包括Nanox.ARC - 這是一種多源數字層析成像系統,成本效益和易於使用;一套基於人工智能的算法(Nanox.AI),可增強常規CT成像的閱讀,以突出與慢性疾病相關的早期跡象;雲基礎架構(Nanox.CLOUD);通過Nanox的子公司USARAD Holdings Inc.提供遠程放射學和心臟病專家的專有分散式市場;以及綜合性遠程放射學服務平台(Nanox.MARKETPLACE)。 Nanox的產品和服務共同創造了一種全球性,創新性和綜合性解決方案,可以從掃描到診斷連接醫學成像解決方案。 要了解更多信息,請訪問www.nanox.vision。www.nanox.vision.

Contacts

聯繫方式

Media Contact:
Ben Shannon
ICR Westwicke
NanoxPR@icrinc.com

媒體聯繫人:
本·香農
ICR Westwicke
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Westwicke
mike.cavanaugh@westwicke.com

投資者聯繫人:
邁克·卡瓦諾
ICR Westwicke
mike.cavanaugh@westwicke.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論